36 min listen
Undruggable Drugs
Froma16z Podcast
ratings:
Length:
29 minutes
Released:
May 6, 2020
Format:
Podcast episode
Description
In this episode of the a16z Podcast, we take a deep dive into the world of drug development—specifically "undruggable drugs": a category of protein, protein family or even piece of RNA that’s so difficult to target that many researchers don’t even want to touch it. Jay Bradner, President of the Novartis Institute for BioMedical Research, shares with a16z General Partners Jorge Conde and Vijay Pande, and a16z's Hanne Tidnam, all the new tools, technologies and breakthroughs which are causing the science of therapeutics to explode in some of these areas where it's been incredibly difficult (even impossible) in the past. From molecular glues to cell and gene therapies, Bradner shares the behind-the-scenes science stories of what it really takes to make a new drug that shatters the category of an "undruggable" target.
Released:
May 6, 2020
Format:
Podcast episode
More Episodes from a16z Podcast
Finding a Single Source of AI Truth With Marty Chavez From Sixth Street: a16z General Partner David Haber talks with Marty Chavez, vice chairman and partner at Sixth Street Partners, about the foundational role he’s had in merging technology and finance throughout his career, and the magical promises and regulatory pitfalls of AI. This episode is taken from “In the Vault”, a new audio podcast series by the a16z Fintech team. Each episode features the most influential figures in financial services to explore key trends impacting the industry and the pressing innovations that will shape our future. by a16z Podcast